Cencora DoD Pharmacy Prime Vendor (PPV) & Understanding the Pharmacy Supply Chain

Aaron Middlekauff, Pharm.D., CAPT, USPHS (ret), SAFP Treasurer

Feb 2025

Conflict of Interests

Aaron Middlekauff declares no conflicts of interest, real or apparent, and no financial interests in any company, product, or service mentioned in this program, including grants, employment, gifts, stock holdings, and honoraria.

Learning Objectives

- Name the pharmacy contracts Cencora partners with DoD in delivering
- List the Cencora contacts or resources to assist in facilitating supply chain issues experienced by DoD
- Identify efficiencies and resources extended as a DoD stakeholder

Pharmaceutical Supply Chain

Supply Chain – Obstacles

- Availability
  - Backorder
  - Short Dating
  - Market Spike
  - Weather
  - DC Stock Level
  - Non-Stock Item (NSI)



Usages

- Changing preferred NDC
- New item monthly usage
- Increase or decrease demand
- Discontinued item

- Service@AmerisourceBergen.com
- 877.774.6329

Year End Pre Book

- Email service@amerisourcebergen.com or call 877.774.6329 to request a "Pre Book“
- Place each manufacturer/vendor on a separate PO
- Allow three days for Amerisource Customer Care to get an approval
- When product arrives at the distribution center it is set aside and not added to inventory
- Or place an 1155 drop ship order

AmerisourceBergen

Government Services & Solutions Team

Marian Benz

SVP, Government Services & Solutions

Alex Merritt

VP, Government Services & Solutions

Aaron Middlekauff

VP, Government Services & Solutions

Aaron Adams

Director, Contract Management



Michael Marquez

Director, Government Account Management, DOD

Jennifer Bennett

Sr. Manager, Government Services & Solutions



Teresa Oakley

Readiness Support, DOD

Yessenia Ramirez

Account Manager, DOD

Sharon Pritchett

Account Manager, DOD

Maureen Kono

Account Manager, DOD

Maria Ramos

Account Manager, DOD

Stephanie Mitchell

Account Manager, DOD

“Good” ‘ol days...


3702 BMTS
3702 BMTS
3702 BMTS FLT 398
SGT DIAZ
TSGT GARZA
NO IT'S NOT
OK
LACKLAND AFB
6 AUG 92



cencora

Cencora is a leading pharmaceutical solutions company centered on improving the health of people and animals around the world

$250+ billion

revenue

Growth aligned with our customers' long-term success

46,000+ team members

- Diverse expertise all focused on improving global health

1,300+ global locations

- Delivering a range of services to address specific, local needs

50+ countries with a local presence

Growing knowledge of market-specific healthcare environments

#11 on the Fortune 500 list

Recognized for breadth and scale

AmerisourceBergen

U.S. Enterprise distribution network

50+ total U.S. distribution facilities

Wholesale

- 25 Wholesale DCs
- 1 National DC
- 1 Generic Rx DC
- 1 Central fill location

Specialty

- 3 Specialty Rx DCs
- 3 3PL facilities

Animal Health

- 12 Animal Health DCs
- 7 Animal Health Depots



Wholesale DC
Specialty Rx DC
Generic Rx DC
Central fill Rx
MWI DC
MWI Depot
3PL
NDC

DSCSA Update

cencora

FDA Grants Exemptions Beyond the Stabilization Period

FDA U.S. FOOD & DRUG ADMINISTRATION

Search Menu

Home / Drugs / Drug Safety and Availability / Drug Supply Chain Integrity / Drug Supply Chain Security Act (DSCSA) / Waivers and Exemptions Beyond the Stabilization Period

Waivers and Exemptions Beyond the Stabilization Period

Share Post Linkedin Email Print

Drug Supply Chain Security Act (DSCSA)

- Drug Supply Chain Security Act Law and Policies
- Drug Supply Chain Security Act (DSCSA) Portal in CDER NextGen
- The Drug Supply Chain Security Act (DSCSA) Waivers, Exceptions, and Exemptions
- Notify FDA of Illegitimate

FDA Grants Exemption to Connected Trading Partners

FDA is issuing an exemption from the enhanced drug distribution security requirements of section 582 of the FD&C Act for eligible trading partners. This exemption applies to any product transacted by eligible trading partners, which are trading partners who have successfully completed or made documented efforts to complete data connections with their immediate trading partners, but still face challenges exchanging data.

More Information:

DSCSA Exemptions from Section 582(g)(1) and Other Requirements of the FD&C Act for Certain Trading Partners

This exemption is part of the agency's broader efforts to avoid supply chain disruptions and ensure patients will not face delays in receiving the medicines they need.

FDA is committed to ensuring patient access to medicines and avoiding supply chain disruptions while continuing significant progress toward full implementation of Drug Supply

Content current as of:
10/09/2024

Regulated Product(s)
Drugs

cencora

FDA Announces Sector Exemptions

October 9th, 2024

FDA has issued an exemption from the enhanced drug distribution security requirements of section 582 of the FD&C Act for eligible trading partners. This exemption applies to any product transacted by eligible trading partners, which are trading partners who have successfully completed or made documented efforts to complete data connections with their immediate trading partners, but still face challenges exchanging data.

- Manufacturers & Repackagers
  Exemption Ends:
  May 27th, 2025

- Wholesale Distributors
  Exemption Ends:
  August 27th, 2025

- Dispensers*
  Exemption Ends:
  November 27th, 2025

*Excludes Small Dispenser Exemption
(November 27th, 2026)

AmerisourceBergen

What does this mean for Cencora?

cencora



What are we “thinking”?

- **Manufacturers & Repackagers**

  - DO NOT STOP
  - If a manufacturer is not sending data at all…
    - This exemption does not apply to them
    - They must get their own WEE before 11/27/2024
  - Current Lot Level transaction (ASNs) must still be provided

- **Cencora**

  - WE ARE NOT STOPPING
  - Continue scanning 100%
  - Continue reporting exceptions to manufacturers
  - Continue ramping up customers with EPCIS / training
  - May 27th, 2025 – targeting “Live” with manufacturers

cencora

Open Threads

Open Threads

Topic:	Due Date:	Notes:
Cencora's WEE and WEE list.	10/31/2024	• FDA has withdrawn Cencora's WEE due to the exemption extension. • COR will no longer be supplying Partners with the WEE NDC list. • Will revisit in 2Q25.
Serialized Returns	10/31/2024	• Serialized returns has been delayed until mid-2025 due to the exemption extension. • COR to provide additional updates in early 2025 which will lay out training and when the functionality will be available to use.

Drop Shipments	Open	• 203 response from 480 MFGs
		  • 134 do not do drop ships
		  • 43 send data today
		  • 14 will in the near future
		  • 12 use only a portal
		• Working with HDA and GS1 to create a standard identifier that all ATPs can use.

cencora

Where are we today?

Where are we today?

- All Cencora DCs are scanning both inbound and outbound.
  - ✓ *Note that at this moment not all EPCIS messages have 100% of the serial #s as some MFGs are still not sending all the data and we are still using the stabilization period to make enhancements at our DCs.*
- NEW DSCSA report live and available in the ‘Reports’ section of ABC Order.
- EPCIS files are flowing daily for those customers that have onboarded with Cencora.
- Exploring exceptions with some of the daily EPCIS messages.

Wholesale Suppliers Status

Supplier EPCIS Status	Supplier Count	% of Total
Live	442	92%
Onboarded	17	4%
In Progress	11	2%
Future Date	9	2%
Open	0	0%
TOTAL	479	100%
TOTAL Connected to Prod	**459**	**96%**



Live suppliers categorized by % data (POs and Units received) – Last 2 weeks
- 100% PO's and 100% Units trending higher





MODS EPCIS Dashboard

- Recent issues with some supplier causing a dip/stagnation
- Mostly issues attributed to 3PLs and solution providers



Location Name	PO Rcvd %	Physical Rcvd %	Order Qty Rcvd %
Amityville	92.28%	95.44%	94.11%
Atlanta (Buford)	95.46%	89.02%	88.29%
Bethlehem	94.01%	83.10%	82.76%
Boston (Mansfield)	94.47%	78.73%	78.21%
Brooks	95.27%	97.65%	97.29%
Chicago	93.33%	90.29%	89.49%
Columbus (Lockbourne)	94.25%	87.04%	86.03%
Columbus NDC (Lockbourne)	95.81%	93.59%	91.86%
Corona	93.02%	87.57%	86.33%
Dallas (Roanoke)	94.68%	87.37%	86.79%
Denver	92.71%	91.92%	91.33%
Dothan	92.71%	70.70%	69.99%
Honolulu	95.24%	112.93%	112.30%
Houston	93.37%	91.37%	90.40%
Indianapolis	94.00%	93.14%	91.71%
Kansas City	94.81%	82.14%	81.36%
Louisville	92.11%	92.30%	91.99%
Montclair	94.55%	90.85%	90.32%
Morrisville	94.05%	92.86%	92.39%
Newburg	93.75%	88.85%	87.83%
Olive Branch	94.30%	85.90%	85.38%
Orlando	93.51%	89.61%	89.15%
Phoenix	93.94%	85.94%	85.25%
Puerto Rico	91.64%	93.40%	92.84%
Richmond	93.82%	88.45%	88.03%
Sacramento	94.91%	83.55%	82.78%
Salt Lake City	92.06%	95.48%	95.23%
Seattle Des Moines	93.20%	93.16%	92.33%
Shakopee	94.74%	93.56%	92.16%
Williamston	93.65%	96.15%	95.56%
Total	**94.04%**	**92.24%**	**90.77%**

cencora

What’s Next?

What's Next?

- If you would like to receive EPCIS files, please send an email to DSCSA_Customer@cencora.com
- Check the NEW DSCSA report in ABC Order for your orders.
- Continue any cadence calls.
- Review data quality of EPCIS files.
- Start to build out and test the exception process with Account Service in early 2025.

AmerisourceBergen became Cencora

What is changing?

- AmerisourceBergen and Alliance Healthcare will become Cencora
- In 2023, the process of adopting a unifying global name and brand will begin

Why are we changing?

- To create a seamless customer and employee experience
- To support our global growth strategy
- To demonstrate differentiated value for the future of healthcare

What can you expect?

- Uninterrupted service
- Communication and transparency as we embark on this transformation
- Unwavering commitment to our purpose

USAMMCE-E RFID **Initiative**

-Third palletized product with RFID tags received

-All systems “go”

-Data aligned and flowing

-New steady state

2024-25 COVID Vaccine Update

AB/Alliance Healthcare Global Reach



AmerisourceBergen

AB Med Tray RFID Solution

Key advantages for our RFID solution

•Pre-tagged products from AmerisourceBergen can save time and reduce costs

•Mountable touchscreen kiosk and hand-held scanner minimize footprint and improve flexibility for hospital-wide monitoring

•Entire medication tray can be scanned in seconds

Medication tray technology features

•Dedicated mobile application for convenient tray management hospital-wide

•Expiry date and tampered product flagging

•Compatible with all storage cabinets

•Online dashboard with real-time data and insights

cencora

FormularyDecisions® for Healthcare Decision Makers

This presentation was created for Cencora (formerly AmerisourceBergen) sales teams to introduce FormularyDecisions to their customers

Last updated March 23, 2024

An online platform and product information resource designed exclusively for healthcare decision makers (HCDMs)



cencora

Complimentary access is available for all eligible HCDMs

Eligibility aligns with the FDA's Guidance on "Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities"

HCDMs review scientific and/or technology assessments to make drug or device selection or acquisition, formulary management, and/or coverage and reimbursement decisions on a population basis

HCDMs represent a multitude of private and public organizations

Hospitals

Health systems

IDNs

PBMs

MCOs

Key: HCDM – healthcare decision maker; FDA – Food and Drug Administration; IDN – integrated delivery network; MCO – managed care organization; PBM – pharmacy benefits manager

cencora

FormularyDecisions® by the numbers

3,000+

FDA-approved and pipeline products*

1 million+

evidence links to scientific resources, including complimentary content exclusively for FormularyDecisions users*

*FormularyDecisions Data on File, 2022

FormularyDecisions

Supporting formulary placement decisions

Access curated pre-approval information, clinical trial summaries, and P&T considerations, created by clinical pharmacists

Review various evidence resources and find research links from leading scientific journals

Request clinical and economic information from numerous biopharma companies

Review national pharmacy and medical coverage data from managed care organizations

Stay up to date on the US biosimilars market landscape, pipeline, and state substitution laws

Conduct P&T reviews using specialized tools

AmerisourceBergen

FormularyDecisions as a central hub for dossier and resource retrieval

“[FormularyDecisions] has been a great resource for our Formulary team. It is much easier to access required Dossiers for drug and class reviews, which includes data unavailable elsewhere (Data on File, models, etc). In addition, it has convenient links to other tools such as ICER reports, formulary kits, articles, etc. — and the pre-approval information helps us plan. It is really nice to be able to go to one place for all of this information."

— Head of Clinical Pharmacy, Managed Care Organization

cencora

Easily manage resources, webinars, and eDossiers in HCDMs' personal FormularyDecisions Inbox



Request resources from any biopharma company





- The **eRequest** button* allows streamlined requests to be made for eDossiers and other resources
- HCDMs can submit requests to multiple biopharma companies in one place

*View to change in Fall 2023

Key: AMCP – Academy of Managed Care Pharmacy; HCDM – healthcare decision-maker; P&T – Pharmacy & Therapeutics Committee.

Interact with eDossiers



- **eDossiers** are digitized dossiers in HTML format that allow HCDMs to toggle between sections to access specific information quickly
- Utilize FormularyDecisions proprietary tools to create notes, bookmark sections, and view 2 eDossiers side by side



Key: HCDM – healthcare decision-maker

Access and review additional information in the Resource Center



Biopharma companies can share relevant product information for HCDM review in the **Resource Center**

- Relevant clinical trial data
- Clinical guidelines or pathways
- Real-world evidence
- Economic models
- Other educational information



cencora

Link to emerging evidence on individual Product Pages, Disease State Pages, Therapeutic Area Pages, and Resource Hubs



Metasearch Results

Note: Metasearch results are based on specified criteria; however, control remains with individual sites for the return of relevant information.

Keyword Filter: medication

Publication Filter: (18) Selected

Publication	Title	Date
National Institutes of Health	Aspirin: Bitter pill or miracle drug? - PubMed	Aug 11, 2021
National Institutes of Health	Miracle drug, poison, or placebo: patients' experiences with	Jun 19, 2021
ClinicalTrials	The Impact of Social Proximity on Conversion to Generic Prescription Medications	May 17, 2021
ClinicalTrials	The Effect of Providing Free Samples of Generic Cardiovascular Medications to Physicians	May 17, 2021
UpToDate	Kidney transplantation in adults: Overview of care of the adult kidney transplant recipient	May 17, 2021
UpToDate	Antiseizure medications: Mechanism of action, pharmacology, and adverse effects	May 17, 2021
UpToDate	Initial treatment of epilepsy in adults	May 17, 2021
UpToDate	Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications	May 17, 2021
Centers for Disease Control and Prevention	Preventing Chronic Disease | Perceptions of and Barriers to Use of Generic Medications in a Rural African American Population, Alabama, 2011 - CDC	May 17, 2021

Rows per page: 10 1-9 of 9

Product Pages contain peer-reviewed articles and documents from leading scientific resources using a metasearch engine, including:

- PubMed
- ClinicalTrials.gov
- Pharmacist's Letter
- The Medical Letter
- Medscape
- Food and Drug Administration (FDA)
- UpToDate.com
- Journal of the American Medical Association (JAMA)
- British Medical Journal (BMJ)
- National Institutes of Health (NIH)
- ...and more!

AmerisourceBergen

Exclusive offerings and curated resources on FormularyDecisions

"FormularyDecisions is a valuable repository of information related to medications and their clinical utility. It is a central source to obtain the basic clinical information, easily compare medications, and evaluate the economic value based on organizational evaluations, like ICER reports."

— Clinical Pharmacist, Health Plan

cencora

Biosimilar Hub



Assess biosimilar value with:

- An organized **table of FDA-approved indications** of biosimilars and their innovator products
- The **latest biosimilars market and pipeline landscape information** categorized by development phase, launch status, and interchangeability
- A dynamic repository of **state substitution laws** and biosimilar products, outlining substitution laws in the states that have passed laws that permit or require pharmacists to dispense an interchangeable biological product in certain situations
- **Curated biosimilar resources**, featuring the latest guidance from FDA, ICER reports, relevant articles, and white papers

Key: FDA – Food and Drug Administration; ICER – Institute for Clinical and Economic Review; US – United States.

cencora

Cell & Gene Therapy Hub



Access cell & gene therapy resources on FormularyDecisions:

- Interact with a comprehensive map of the **CGT landscape**, nearly organized by therapeutic area
- Find **pipeline, approved, and launched therapies**, each accompanied by key details like manufacturer, phase, approval year, launch status, and FDA designations
- Dive deeper with **curated publications and reports** from trusted sources like the Alliance for Regenerative Medicine, the American Society of Gene and Cell Therapy, and the FDA

Key: CGT – cell & gene therapy

Formulary Coverage Insights and Data



Obtain insights on how peer organizations are managing coverage and restriction of products

Find this tool on the Product Page of every FDA-approved product

Data is sourced from MMIT (Managed Markets Insight and Technology)

cencora

Product Snapshots

Product Overview

Manufacturer	Funentech, Inc.
Status	PDUFA date: 05/10/2030
Proposed indication	Miracles in patients with miracle deficiency
Therapeutic class	Miracle receptor agonist (MRA)
Mechanism of action	Pharmacodynamic studies have shown that miraculate selectively binds and agonizes the miracle receptor in the central nervous system (CNS), which activates downstream miracle signaling in patients with miracle deficiency[1]
Formulation	Oral tablet
Dose and administration	• Dosing: 300 mg twice daily • Route of administration: oral • Setting of administration: outpatient

Curated by clinical pharmacists, Product Snapshots are a source of product information to help HCDMs jumpstart the product review process. With a focus on pre-approval products, Product Snapshots contain the following pieces of key information:

- Manufacturer
- PDUFA date
- Approved indication(s)
- Therapeutic class
- Mechanism of action
- Dose and administration
- Epidemiology of disease
- Distinguishing factors of product
- Relevant disease background and treatment guidelines
- Key comparators
- Clinical trials overview
- P&T considerations

Key: PDUFA – Prescription Drug User Fee Act; FDA – Food and Drug Administration; P&T – Pharmacy & Therapeutics Committee.

cencora

Clinical Guideline Snapshots



Curated in collaboration with *The Medical Letter*, Clinical Guideline Snapshots provide a summary of key information from published clinical guidelines and highlight the most recent updates for specific disease states.

What type of information is provided in the Clinical Guideline Snapshots?

- **Clinical guideline overview**
  - ✓Date of last guideline publication
  - ✓Summary of clinical guideline
  - ✓Changes since the last guideline publication
  - ✓Epidemiology of relevant disease state
  - ✓Treatment algorithms
- **Clinical considerations**
  - ✓Recommendations and strength of recommendations
  - ✓Recommendations for specific products
  - ✓Recommendations for specific populations

AMCP Pre-approval Information Exchange (PIE) Webinars



AMCP PIE webinars allow HCDMs to:

- Participate in an early, meaningful, and effective exchange of information for preapproval products
- Plan for future drug approvals and reimbursement decisions and forecast future budgets

Key: AMCP – Academy of Managed Care Pharmacy; HCDM – healthcare decision-maker; PIE – pre-approval information exchange.

cencora

Register today for your complimentary FormularyDecisions account at www.formularydecisions.com/register

AmerisourceBergen

U.S. Opioid Settlement Injunctive Relief

July 2022

AmerisourceBergen

What is Injunctive Relief?

- In March 2022, AmerisourceBergen, Cardinal and McKesson agreed to a nationwide settlement that resolves most of the thousands of opioid-related lawsuits filed by state and local government entities across the country.
- As part of the agreement, court-ordered injunctive relief will apply to each distributor's Controlled Substance Monitoring Program (CSMP) to ensure consistency across the industry.
- The injunctive relief terms will go into effect on July 1, 2022, and will impact all customer who are registered with the DEA as a retail pharmacy including independents, chains and mail order pharmacies.
- For the latest information and details about injunctive relief, visit: amerisourcebergen.com/injunctiverelief

AmerisourceBergen

What's changing?

- AB will be making changes to our **Controlled Substance Monitoring Program (CSMP)**. These changes will ensure consistency in our approach to Controlled Substance distribution across the industry and will impact how we conduct diligence reviews, data collection and analysis, monthly limits on controlled substance ordering, and suspicious order reporting.

A higher quantity of order lines will be flagged – flagged order lines will be automatically cancelled and reported.

- Our new algorithm is designed to automatically flag order lines of unusual size, frequency or pattern
- Order lines that are flagged by the algorithm will be automatically cancelled and reported
- Only the lines of your order that are flagged will be cancelled, the rest will ship.
- If you're routinely having items cancelled and are unable to meet legitimate medical needs of your patients, there's a process to request a threshold review



AB will make unannounced pharmacy visits to observe and speak with the responsible pharmacist.

- Historically, we've notified you in advance if we needed to do an on-site visit for due diligence.
- As part of the settlement agreement, we are required to make unannounced visits.
- These may be performed by our third-party partner, Pharma Compliance Group (PCG) – they will provide identification credentials
- You may contact your AB representative to validate that it is a legitimate visit

We will be required to collect 90 days of de-identified dispensing data from you more frequently

- Please ensure you have processes in place to efficiently turn over this data to AB or our HIPPAA-compliant technology vendor, when requested
- If you request a threshold review, you will also be required to submit this information in support of your request.

Current AB POC’s

AmerisourceBergen

DOD CONTACT LIST

DOD Accounts Receivable	CONTACT NAME	EMAIL	PHONE
	A/R Team	DODAR@amerisourcebergen.com	866-858-0599
	Terry Tyo, Supervisor	ttyo@amerisourcebergen.com	Mon - Fri: 8am -5pm (EST)
	Catalina Montoya	cmontoya@amerisourcebergen.com	
	Ileana Echevarria	iechevarria2@amerisourcebergen.com	
	Sirry Henry	shenry@amerisourcebergen.com	
	Yolaiza Crouch	yolaiza.crouch@amerisourcebergen.com	
Account Services	A/S TEAM	accountservicesCSP@amerisourcebergen.com	844-234-0546
	Jeremy Miller, Manager	jemiller@amerisourcebergen.com	484-644-5198
	Kimberly McClain-Wilkerson	kmcclain-wilkerson@amerisourcebergen.com	630-276-4200 X 1352591
	Maria Barrios	maria.barrios@amerisourcebergen.com	610-727-2265
DOD AXL LIASON		axldod@amerisourcebergen.com	
	Sharon Pritchett (East)	spritchett@amerisourcebergen.com	609-364-3656
	Yessenia Ramirez Robles (West)	yramirez@amerisourcebergen.com	630-200-2570
Customer Systems Support User Services/ Technical Support		customersystemssupport@amerisourcebergen.com	888-711-5469
AB ORDER Account Setup	Deanne Spears, CSS Specialist	dwspears@amerisourcebergen.com	610-727-2463
AB ORDER Account Setup/ Tech Supp		Customersystemssolutionsspecialists@amerisourcebergen.com	
DOD Customer Maintenance	Denise Polen	CIDM@Amerisourcebergen.com	614-354-2945
	DOD Customer Maintenance	dpolen@amerisourcebergen.com	
DOD Customer Service	Mon - Fri 7am - 11pm (CST)	DODservice@amerisourcebergen.comm	844-222-2273
National Customer Support		DODsupport@amerisourcebergen.com	OR 877-774-6329
			FAX 888-294-0857
OCONUS Customer Service	Mon - Fri 7am - 11pm (CST)	dodoconus@amerisourcebergen.com	855-283-1104
EDI	Rob Such	rsuch@amerisourcebergen.com	847-307-8580
	B2B EDI Data Exchange	edisupport@amerisourcebergen.com	
		DESEDIB2B@amerisourcebergen.com	
ASD Healthcare	Available 24/7	Customer Service	800-746-6273 OR
			800-837-5403
ASD AFTER HOURS		EMERGENCY, WEEKENDS AND HOLIDAYS	877-639-6390
Sr Director Government Business Development - HS&SS	Alex Merritt	amerritt@amerisourcebergen.com	312-533-8015
Sr Director Government Business Development - HS&SS	Aaron Middlekauf, Pharm.D. CAPT, USPHS (ret)	aaron.middlekauff@amerisourcebergen.com	703-223-4148

PPV Program Overview

- Current Global PPV contract expired Nov 2024 (bridge in place until Nov 2025)
- MTFs worldwide (except Navy's fleet contract & Dakota's)
- Emergency Orders
- Reverse Distribution Program
- DMS back-up PPV supplier
- National Prime Vendor Contract (17 Dec 2022)/ TPharm5 (1 Jan 2023)

Optimizing Stockage of Gov Contract Meds, Solutions

- Government contracts/rebates
- TAA compliance/NAD
- Stock levels

Supply Chain – not every disruption is caused by regulatory or facility issue (ie-Tripledemic, GLP-1's, ADHD Med Therapy)

Most GLP-1's

- Obesity vs Diabetes Interplay
- Brand marketing tactics/bait and switch for maintenance tx
- Significant demand/major shortages

ADHD Meds

- Change in prescribing dynamics
- Increased media attention
- Inc Demand/Significant Shortages
- Inc prescribing/Pandemic/Mental Illness/Telehealth Access

DoD Pharmacy Customer Service Topics

AmerisourceBergen

GPV - Over 13K DOD related cases created July– September 2024

Customer Service	• Returns & Claims • Order Status • Standard Order
Account Services	• Fail to pick • Purchase History Reports • Delayed Deliveries
Account Management	• Product Inquiry • Standard Order • Contracts Inquiries
Customer System Support	• Administrative • Multifactor Authentication • New Account Activation
Account Maintenance	• Account Setup • Item eligibility Requests • General Account Maintenance
Accounts Receivable	• AR Inquiry



GPV Fill Rate Review





PROGRAM	July	August	September
DLA	97.4%	97.1%	96.9%
Cencora	97.2%	97.2%	97.3%

USAMMCE	July	August	September
DLA	83.5%	86.9%	77.9%
Cencora	90.1%	93.9%	89.8%

ABC Order Integration – inventory, order optimization, etc.

ABC Order
AmerisourceBergen

DEPARTMENT OF DEFENSE
MHS GENESIS®
MILITARY HEALTH SYSTEM

Post-Retirement Advice

-TAPS

-Partner with veterans' group

-A lot of changes on the horizon

MTF & DC Visits

Self Assessment Questions

- Pharmaceutical Prime Vendor Program Overview
- Drug Supply Chain, Optimizing Stockage of Gov Contract Meds, Solutions
- Remedies to Common Problems

Self Assessment Questions

- Name the pharmacy contracts AB partners with DoD in delivering:
- Global Prime Vendor and National Prime Vendor

- List the AB contacts or resources to assist in facilitating supply chain issues experienced by DoD:
- Government Team – Account Managers, Teresa Oakley, A/R, Contracts, DSCSA

- Identify efficiencies and resources extended as a DoD stakeholder:
- ABC Order, MedTray, Supply Chain Insight

Enjoy your time in Tokyo!!!

CPE Information

To earn CPE credit, follow the steps below:

1) Visit the link below to access the CPE Site for this activity: https://tinyurl.com/ReadyMedServices

2) Post-Event Evaluation for this CPE activity using the GREEN registration button (if you have not claimed CE credit through the UT Austin College of Pharmacy CPE site before, you will be prompted to create a CPE profile before you may register for this activity).

3) After you are registered for the activity, submit the green evaluation button that will appear (please note: the evaluation will remain inactive until the last session is scheduled to end).

4) Upon submitting the online evaluation, CPE Credit will automatically upload to your NABP CPE Monitor profile (allow 2-3 days).

5) **Evaluations must be completed before June 20, 2023 or you forfeit CPE credit.**

6) IMPORTANT NOTE: It is the participant's responsibility to check their online CPE Monitor Profile to confirm CPE credit is accurately reflected or contact UT Continuing Pharmacy Education before August 5, 2021 to resolve any discrepancies. CPE credit cannot be awarded or corrected after 5.

Attendance Code

https://tinyurl.com/ReadyMedServices

Questions?